anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine. ^ SUBSTANCE: invention concerns normalising functional reactivity of cardiovascular system (CVS) in arterial hypertension, dyslipidemia, impaired glucose tolerance and abdominal obesity. That is ensured by estimating the condition of functional reactivity of the CVS in psychoemotional load, with recording systolic, diastolic, average dynamic pressure (PBav.dyn.) and heart rate (HR). These data are used to evaluate a functional responsiveness index (FRI) before and after stress by formula: FRI=(BPav.dyn. x HR)/100 (standard units). The post-load value PFR increased more than by 20 standard units requires the complex therapy including individually prescribed hypocaloric diet calculated by formula considering sex and age, rationally graduated static and dynamic physical activity, and introduction of losartan in a dose of 50 mg once in the morning, and pioglitazone in a dose of 30 mg once in the morning at least within 4 months. ^ EFFECT: such complex drug-induced and drug-free therapy combined with empirically prescribed treatment length provides normalisation of functional reactance of the CVS in the given group of the patients due to potentiation of therapeutic effect of separate components of an individual care. ^ 1 ex
This is an investigator-initiated double-blinded study in which one hundred and eighty male and female subjects ages 6 to 10 will be recruited from the Division of Pediatrics at Boston University Medical Center. Potential volunteers will undergo a screening process to ensure that inclusion and exclusion criteria are met. A general medical history will be taken before the study starts. A baseline biochemical profile (blood) including calcium, phosphorus, osteocalcin, alkaline phosphatase, C-telopeptide (CTX), 25(OH)D, PTH, albumin, vitamin A, and vitamin E will be determined after the study is completed. The amount of blood estimated to be drawn on the first visit is 27 ml. Dietary intake will be assessed from 3 day food records via NDS-Minnesota Database by Dr. Christine Economos, Friedman School of Nutrition Science and Policy at Tufts University. Once the subject has met the inclusion criteria, he/she will receive two gallons of orange juice via a delivery service to their home. He/she will be instructed to drink two 8 oz. glasses of orange juice a day and record each glass of juice that was drunk; stickers and calendars will be provided. A delivery service will be used to deliver juice to parents/caregiver biweekly. Signature and log sheets of deliveries will be maintained. A glass that has a mark designating eight ounces will be provided to the subject so that the amount of orange juice that is drunk is measured. Sixty subjects will receive intervention A, sixty subjects will receive intervention B, and sixty subjects will receive intention C. Subjects randomized to intervention A will receive juice that contains 200 IU of vitamin D and 700 mg of calcium per day. Subjects randomized to intervention B will receive 200 IU vitamin D, 12 IU vitamin E, 2000 IU vitamin A as beta-carotene, and 700 mg of calcium per day. Subjects randomized to intervention C will receive 700 mg calcium per day. A venous blood sample of 27 ml \[two red top tubes (10ccs each) and one purple top tube (7ccs)\] will be obtained at the initial and final visits. 25(OH)D, PTH, calcium, phosphorus, osteocalcin, C-telopeptide(CTX), alkaline phosphatase, albumin, vitamin A, and vitamin E will be measured from the blood samples. During the mid-intervention blood draw (week 6) 10mL of blood will be drawn and 25(OH)D and PTH will be measured. The study will consist of 12 weeks of drinking two eight-ounce glasses of orange juice a day (one in the am and one in the pm).
<P>PROBLEM TO BE SOLVED: To provide a soft capsule having a water-soluble film and capable of including contents containing water without causing leakage of the contents.  <P>SOLUTION: The soft capsule has the film containing gelatin and a water-soluble polymer and contents included in the film. The contents of the soft capsule contain a metal salt and a desired material. In a preferable soft capsule, the water-soluble polymer is contained in an amount of 1-20pts.wt. based on 100pts.wt. gelatin and the metal salt is contained in an amount of 1-10pts.wt. based on 100pts.wt. water in the contents.  <P>COPYRIGHT: (C)2004,JPO
Liver transplantation (LT) is the most effective treatment modality in patients with end-stage liver disease and it is also established as a viable treatment option in the field of oncology. Living donor liver transplantation (LDLT) using the right lobe (RL) is a major achievement despite its technical challenges, which has created a significant increase in graft supply. While a secure bile duct anastomosis is one of the basic principles of a successful liver transplant procedure, biliary reconstruction remains the Achilles' heel of LDLT because of the high incidence of posttransplant biliary complications associated with significant recipient morbidity and mortality. Some of these complications are related to technical difficulties due to multiple small biliary orifices, particularly in right lobe grafts. In our center, we have been using microsurgical reconstruction technique for duct-to-duct biliary anastomosis in such grafts. The routine use of this technique has been shown to significantly decrease biliary complications in single-center retrospective studies. However, prospective controlled studies comparing microsurgical and standard biliary reconstruction techniques are lacking. In this study, our objective is to compare posttransplant complications of the two techniques of biliary reconstruction in RL LDLT.

40 patients will be included in the study. They will be randomly allocated in the equal groups.İn group 1 biliary anastomosis will be performed using surgical loupes and İn group 2 biliary anastomosis will be performed using microscope. The patients will be followed for one year after the transplant to compare biliary complications.
PURPOSE: A lipoteichoic acid-derived glycolipid and pharmaceutical, food, and cosmetic composition are provided to ensure anti-inflammation effect by suppressing inflammatory cytokine. CONSTITUTION: A lipoteichoic acid-derived glycolipid contains 2-6 saturated or unsaturated acyl chain of C10-C30 at one site of C1, C3, C4 and C6 site of double or triple hexose. The glycolipid has a structure of chemical formula I. Bacteria includes Lactobacillus, Bifidobacterium, Streptococcus, or Lactococcus. The glycolipid is additionally bound with polyphosphoric acid glycerol at C6 site of hexose in which an acyl chain is not bound. A pharmaceutical composition for preventing and treating inflammatory diseases or immune diseases contains lipoteichoic acid-derived glycolipid and additionally contains antibiotics, carrier, excipient, or diluents. The pharmaceutical composition is manufactured in the form of powder, granule, tablet, capsule, suspension, emulsion, syrup, suppository, or sterilized injection.
A method for facilitating a health protection protocol is presented. The present invention provides the storage device, the processing device, the health tracking device, and the at least one user interface device, where the health tracking device contains at least one sensor, at least one user biological data is received through the at least one sensor. At least one user biological data is transmitted from the health tracking device to the at least one user interface device. The at least one user biological data is transmitted from the at least one user interface device to the storage device. The plurality of health data is updated with the at least one user biological data through the processing device. The plurality of health data is transferred to the at least one user interface device. An at least one health statistic is generated from the plurality of health data through the processing device.
The invention discloses a millettia specisoa Champ. steaming liquor and a preparation method thereof. The millettia specisoa Champ. steaming liquor comprises rice wine, millettia specisoa Champ., philippine flemingia root, herba dendrodii officinalis, radix achyranthis bidentatae, eucommia bark, radix morindae officinalis, twig and leaf of creeping psychotria and fructus liquidambaris. When comprising one L of rice wine, the millettia specisoa Champ. steaming liquor comprises 100-200g of millettia specisoa Champ., 10-30g of philippine flemingia root, 5-15g of herba dendrodii officinalis, 5-15g of radix achyranthis bidentatae, 5-15g of eucommia bark, 4-12g of radix morindae officinalis, 3-7g of twig and leaf of creeping psychotria and 3-7g of fructus liquidambaris. The millettia specisoa Champ. steaming liquor is prepared according to the steps of soaking the millettia specisoa Champ., the philippine flemingia root, the herba dendrodii officinalis, the radix achyranthis bidentatae, the eucommia bark, the radix morindae officinalis, the twig and leaf of creeping psychotria and the fructus liquidambaris into the rice wine according to a specific ratio, sealing primary liquid in a jar, subjecting the millettia specisoa Champ. steaming liquor primary liquid to double distillation, filtering the primary liquid to keep a solution and sterilizing the solution so as to obtain the millettia specisoa Champ. steaming liquor. The millettia specisoa Champ. steaming liquor is prepared according to the strict formula ratio and has good treatment effects on deficiency of the kidney, deficiency of vital energy, waist soreness, leg pain, lumbar muscle degeneration, rheumatism, bone diseases, chronic hepatitis, bronchitis, pulmonary tuberculosis and the like.
Buprenorphine Sublingual Tablets are uncoated oval orange tablets, imprinted with a logo on one side and a numeric imprint on the other side. The tablets contain buprenorphine HCl and are available in two dosage strengths, 2 mg buprenorphine and 8 mg buprenorphine (as free base). Each tablet also contains citric acid anhydrous, crospovidone, FD&C yellow #6 HT aluminum lake, lactose monohydrate, magnesium stearate, mannitol, pregelatinized starch (maize), povidone, sodium citrate dihydrate.

Chemically, buprenorphine HCl, USP is (2S)-2-[17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-6-methoxy-6α,14-ethano-14α-morphinan-7α-yl]-3,3-dimethylbutan-2-ol hydrochloride. It has the following chemical structure:

Buprenorphine HCl, USP has the molecular formula C 29H 41NO 4•HCl and the molecular weight is 504.10. It is a white or off-white crystalline powder, sparingly soluble in water, freely soluble in methanol, soluble in alcohol and practically insoluble in cyclohexane.
Soft gelatin capsules containing 1g pure EPA-EE equivalent to 914mg EPA-FFA. Administered as 4g per day to be taken as 2 capsules in the morning and 2 capsules in the evening.
PROBLEM TO BE SOLVED: To provide a loxoprofen.sodium-containing tablet formulation capable of readily formulating, quickly decomposing at inside of stomach and absorbing an active component through an alimentary canal in a case of orally administrated. SOLUTION: This loxoprofen.sodium-containing tablet formulation is composed of (a) 1 pt.wt. of loxoprofen.sodium, (b) 2.85-2.90 pts.wt. of a filler as milk sugar and/or corn starch, (c) 0.40-0.45 pt.wt. of a disintegrator as low- substituted hydroxypropylcellulose, (d) 0.07-0.075 pt.wt. of a lubricant as magnesium stearate and (e) a minute amount of iron sesquioxide, and contains the loxoprofen.sodium as an anhydride in an amount of 20wt.% based on a total weight of a formulation.
BACKGROUND: Radical cystectomy and ileal conduit have a high incidence of surgical site infection. In this study, we evaluated the effects of preoperative immunonutrition on its incidence following these procedures.
MATERIALS AND METHODS: We retrospectively enrolled 86 patients who underwent radical cystectomy and ileal conduit at our hospital between 2014 October and 2021 July. They were sequentially divided into the Immunonutrition group (n = 43) and Control group (n = 43). Patients in the Immunonutrition group drank 4 packs of IMPACT (Nestle, Japan) per day for 5 days before surgery. IMPACT contains arginine and eicosapentaenoic acid. We compared levels of plasma arginine and eicosapentaenoic acid before and after surgery and the rate of surgical site infection between the groups. Factors related to surgical site infection were analyzed using univariate and multivariable logistic regression analysis.
RESULTS: No statistically significant differences were observed in patient characteristics between the groups except for surgical operative method (P < .001) and transfusion (P = .009). Levels of plasma arginine and eicosapentaenoic acid were significantly increased the day before surgery in the immunonutrition group (P < .001). However, the levels of plasma arginine on the day after surgery did not vary significantly between the groups. The incidence of surgical site infection was significantly lower in the immunonutrition group (P = .014). Multivariate analyses showed a significant association of surgical site infection with immunonutrition (OR = 0.14, CI 0.03-0.72, P = .019) and with ASA classification (OR = 4.76, CI 1.23-18.40, P = .024).
CONCLUSIONS: Preoperative immunonutrition significantly reduced the incidence of surgical site infection following radical cystectomy and ileal conduit.
BACKGROUND: The relation between phosphorus (P) intake and obesity is equivocal, with hypotheses in both directions.
OBJECTIVES: We investigated the relationship between P intake, assessed from a current database, and calculated bioavailable P intake and obesity among African-American adults.
METHODS: We examined associations between original and bioavailable P (total, added, and natural) and BMI and waist circumference (WC) in a cross-sectional study of 5306 African-American adults (21-84 y) from the Jackson Heart Study. A total of 3300 participants had complete interviews, valid dietary data, and normal kidney function. Diet was assessed by food frequency questionnaire. A novel algorithm was used to estimate P bioavailability. BMI or WC was regressed on each P variable, adjusting for total energy intake and potential confounders.
RESULTS: After adjusting for covariates, original P (total and added) and bioavailable P (total and added) intakes (expressed/100 mg) were associated with BMI (β: 0.11, 0.67, 0.31, and 0.71, respectively; all P < 0.0001). Neither original nor bioavailable natural P was significantly associated (β: -0.03 and 0.09, respectively; both P > 0.05). When added and natural P were included in the same model, added P (original and bioavailable) intakes remained strongly associated with BMI (0.70 and 0.73, respectively; both P < 0.0001). Similar results were seen for WC. Intake of original added P tended to be more strongly associated with BMI, in females (β: 0.72; P < 0.0001) than in males (β: 0.56; P = 0.003) (P-interaction = 0.06).
CONCLUSIONS: We found that greater intake of added, not natural, which may be a proxy for intake of processed foods was associated with higher BMI and WC. These were somewhat stronger when bioavailability was considered and for women than for men. Further investigation is needed to fully understand the mechanisms driving these associations.
PURPOSE:To obtain the titled preparation composed of 5-fluorouracil, a medium- chain fatty acid glyceride and water, agreeable to take, and having excellent absorbability and retainability in the body, and reduced side effects. CONSTITUTION:The objective emulsion preparation is obtained by emulsifying 5-fluorouracil which is an excellent antimetabolic carcinostatic agent, in water using a medium-chain fatty acid glyceride, preferably an 8-12C fatty acid triglyceride as an oil phase. The amounts of fluorouracil and the fatty acid triglyceride are 0.1-5pts., preferably 0.5-2pts., and 1-50pts., preferably 5-20pts. per 100pts. of water. If necessary, a surface active agent (especially a nonionic surface active agent) and a binder are added to the emulsion as emulsion stabilizers.
This study was a 4-week, randomized, controlled, crossover clinical trial. Arm 1: Volunteers will be randomize to be allocated to eat 350g/week of "kent'erbas" pecorino from extensive farming with a crossover with arm 2 after 6 weeks of washout.
Patients receive ZEN003694 PO once or twice daily on days 1-14 or days 1-21 of each cycle depending upon dosage assignment. Patients also receive etoposide IV over 60 minutes on days 1-3 for cycles 1-4 or up to 8 cycles, and cisplatin IV over 60 minutes on day 1 of cycles 1-4 or up to 8 cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may undergo radiologic evaluation (chest x-ray, CT, PET-CT, MRI, and/or FDG-PET), blood and urine sample collection and biopsy throughout the study.
The Reducing Overuse of Antibiotics at Discharge (ROAD) Home study is designed to test the hypothesis that hospitals randomized to an implementation intervention that includes external facilitation to support participants while allowing for free choice in selecting and implementing evidence-based antibiotic stewardship strategies based on local context will have fewer days of antibiotic overuse at discharge than "stewardship as usual" control hospitals. The first aim of this study is to evaluate the effectiveness of the ROAD Home Intervention on days of antibiotic overuse at discharge for hospitalized patients treated for CAP and UTI. The second aim of this study is to identify contextual factors influencing the implementation of the ROAD Home Intervention and to assess implementation outcomes (acceptability, feasibility, fidelity, and sustainment) to inform future broad dissemination.

A two-arm, parallel, cluster-randomized trial will assess the effect of the ROAD Home Intervention on days of antibiotic overuse at discharge. Forty hospitals will be recruited from the Michigan Hospital Medicine Safety Consortium (HMS; https://mi-hms.org/), a statewide 69-hospital collaborative consisting of diverse hospitals and focused on improving the care of hospitalized patients. HMS hospitals that agree to participate will undergo covariate-constrained randomization to improve balancing of critical hospital characteristics between groups with 1:1 allocation to the ROAD Home intervention vs. a "stewardship as usual" control. In the 12- to 15-month intervention period, hospitals will implement the intervention while investigators assess days of antibiotic overuse at discharge and patient outcomes. During the intervention period and in the 9-month post-intervention period, investigators will conduct a theory-informed mixed-methods process evaluation to evaluate barriers, facilitators, and implementation outcomes across hospitals.
The present invention discloses a computer system for providing athlete metrics having a data storage tier, a server tier, a client tier and a connectivity tier. The data storage tier may be capable of storing player and team metrics data or performance data, along with external data. All data collection and storage may be capable of occurring in real time, meaning, contemporaneously with and occurrence of the even the data represents. The client tier may be capable of collecting and displaying said player and team metrics data from a plurality of input sources. The server tier may be capable facilitating communication between the client tier and the data storage tier, as well as for having computer logic for parsing and organizing conditioning data that is being recorded and reviewed at the client tier. The computational logic may be written in any computer language, disclosed herein, and other languages, and enables the present invention to establish a correlating relationship between player testing and evaluation metrics data and performance data, and team metrics that is then used to create forecasts, make decisions regarding the future, and provide feedback and direction for day to day operation of a sports industry enterprise, such as a sports team. The usage of the client is facilitated with a dashboard style interface that standardizes various implementations and applications of the present invention.
The purpose of the Manual Cervical Distraction (MCD): Measuring Chiropractic Delivery for Neck Pain Clinical Trial is to examine the patient-centered clinical and biomechanical outcomes, and believability characteristics of a manually-localized cervical distraction procedure for the treatment of neck- or neck-related arm pain or disability. One challenging issue in the study of manual therapies, including spinal manipulation (SM), is the development of sham and/or minimal intervention procedures suitable for use with control groups in clinical trials. With SM, active treatment requires substantial physical contact between a study clinician and the study participant, either directly or through a mechanical intermediary. Consequently, it is difficult to introduce differences in manual therapy procedures that distinguish sham and/or minimal interventions from the active treatment, but are not immediately obvious to the study participant. Another challenging issue is training clinicians to deliver a standardized SM treatment within specified force ranges. The muscles surrounding the neck could alter the forces transmitted to the cervical spine, and could alter the treatment effectiveness. The purpose of this pilot randomized controlled trial is to examine the patient-centered clinical, biomechanical, and believability outcome characteristics of a manually-localized cervical distraction procedure for the treatment of neck or neck-related arm pain or disability. We also will evaluate the ability of the doctor of chiropractic to deliver the MCD treatment within specified force ranges. An exploratory aim of this study is to evaluate EMG measurement during MCD delivery.
BACKGROUND: Revision of failed total ankle replacement (TAR) is challenging and associated with increased morbidity. Given the increased popularity of TAR in treating end-stage ankle arthritis (ESAA), viable revision options are needed. The objective of this case series is to present a minimum 2-year clinical and radiographic outcomes of patient-specific custom 3D-printed total ankle total talus (TATR) prostheses in this unique subset of patients.
METHODS: 19 participants with ESAA and failed primary TAR who underwent TATR by a single surgeon at our institution from 2019 to 2021 were retrospectively identified. All participants were indicated for revision of primary STAR implant (Stryker, Kalamazoo, MI) and underwent replacement with 3D-printed titanium implants based on preoperative CT analysis (Additive Orthopaedics, Little Silver, NJ). Custom components included a mobile-bearing total talus and stemmed tibial system, performed through an anterior approach. Pre- and postoperative patient-reported outcomes were assessed using the Patient Reported Outcomes Measurement Information System (PROMIS). Pre- and postoperative implant alignment was assessed using medial distal tibial angle (MDTA) and tibiotalar angle (TTA) on anteroposterior, and sagittal tibial angle (STA) on lateral weight-bearing plain films.
RESULTS: The average patient age was 60.6 (range, 39-77) years, with an average follow-up of 37.9 (range, 25.3-57.5) months. There was statistically significant improvement in all PROMIS domains. Short-term survivorship was 100%, with two participants (11.0%) requiring reoperation for postoperative complications: one underwent open reduction internal fixation of the tibia for a periprosthetic fracture, and another underwent medial gutter debridement and tarsal tunnel release for recurrent pain. There were no significant differences in pre- versus postoperative radiographic alignment measured by MDTA (89.9 vs 86.4), TTA (89.7 vs 88.1), or STA (85.2 vs 85.3).
CONCLUSION: Custom 3D-printed TATR is a promising option for revision TAR. There was significant short-term improvement in pain and physical function, with excellent short-term survivorship and an acceptable postoperative complication rate.